This policy does not certify benefits or authorization of benefits, which is designated by each individual policyholder contract. Paramount applies coding edits to all medical claims through coding logic software to evaluate the accuracy and adherence to accepted national standards. This guideline is solely for explaining correct procedure reporting and does not imply coverage and reimbursement.
The Advisory Committee on Immunization Practices (ACIP) recommends Zostavax for people aged 60 years and older. The studies revealed the highest level of efficacy was for people 60-69 years of age. Since this is still a fairly new vaccine, there are still questions that have not been answered, such as concurrent vaccine administration and duration of protection. These risks and benefits need to be discussed between the member and their physician prior to the administration of the vaccine. It has been determined that even people who have had herpes zoster should receive the vaccine to help prevent future occurrences of the disease.
On October 20, 2017, the U.S. Food and Drug Administration (FDA) licensed Shingrix (zoster vaccine recombinant, adjuvanted; GlaxoSmithKline) for adults aged 50 years and older to prevent shingles (herpes zoster).
On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) voted that Shingrix is:  recommended for healthy adults aged 50 years and older to prevent shingles and related complications  recommended for adults who previously received the current shingles vaccine (Zostavax®) to prevent shingles and related complications  the preferred vaccine for preventing shingles and related complications POLICY Shingrix (90750) (zoster vaccine) does not require a prior authorization for ages 50 and above.
Zostavax (90736) (zoster vaccine) does not require a prior authorization for ages 60 and above.
Paramount considers Shingrix & Zostavax (zoster vaccines) experimental and investigational for any indication other than to reduce the risk of herpes zoster (e.g., autologous and allogeneic hematopoietic transplant recipients, individuals with chronic lymphocytic leukemia) because its effectiveness for these indications have not been established.
Paramount allows members who previously received Zostavax to now receive Shingrix. Zostavax (zoster vaccine) is considered a covered benefit to reduce the risk of herpes zoster (shingles) under the medical benefit based on the member's individual coverage limitations, and policy coverage guidelines for members ages 60 and older.
Elite Shingrix (zoster vaccine) is only covered under the pharmacy benefit (Medicare Part D) to reduce the risk of herpes zoster (shingles) for members ages 50 and older, and is not reimbursed by Paramount as a medical service. This vaccine will be denied if it is billed by any provider as a medical claim.
Zostavax (zoster vaccine) is only covered under the pharmacy benefit (Medicare Part D) to reduce the risk of herpes zoster (shingles) for members ages 60 and older, and is not reimbursed by Paramount as a medical service. This vaccine will be denied if it is billed by any provider as a medical claim. 
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